The FDA has approved a new drug called Nuplazid (pimavanserin) for treating hallucinations and delusions caused by Parkinson's disease psychosis. This is the first medication ever approved specifically for this condition. Parkinson's disease psychosis can be very distressing for patients and their families. Until now, doctors had to use other antipsychotic drugs that often made movement problems worse.
Nuplazid is for adults with Parkinson's disease who experience hallucinations (seeing or hearing things that are not there) or delusions (false beliefs). In a 6-week study of 199 patients, those taking Nuplazid had fewer psychotic symptoms than those on placebo. Importantly, the drug did not worsen motor function, which is a common side effect of other antipsychotics.
This approval gives doctors a new tool to help manage these challenging symptoms. However, it is not a cure for Parkinson's disease. Patients should talk to their doctor about whether Nuplazid is right for them, as it may not be suitable for everyone. As with any medication, there are potential side effects and risks, including a possible allergic reaction.